1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
27,36,000 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 50.12 | 32.75 | 17.10 |
| Total Income | 46.12 | 24.48 | 1.72 |
| Profit After Tax | 4.26 | 1.93 | -0.93 |
| EBITDA | 9.21 | 4.57 | -0.69 |
| NET Worth | 9.47 | 5.21 | 3.27 |
| Reserves and Surplus | 5.22 | 0.96 | -0.98 |
| Total Borrowing | 19.14 | 19.22 | 10.35 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹158.00 |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹36.50 |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹166.00 |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹270.00 |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹307.70 |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹198.35 |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹339.90 |
| Symbiotec Pharmalab Ltd. | Mainboard | ₹1,757.00 Cr | ₹988 | 55.44 | ₹1,097.70 | +11.10% | ₹1,133.45 |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹67.99 |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹523.35 |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,236.10 |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,835.40 |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment in full or in part, of certain of our outstanding borrowings | 9.00 |
| 2 | Funding capital expenditure towards purchase of new machinery | 6.08 |
| 3 | Funding to meet Working Capital requirements | 15.00 |
| 4 | General Corporate Purpose |
About Rednex Pharmaceuticals IPO
Updated on Dec 31, 2025
Contact Details
Rednex Pharmaceuticals Ltd. AddressSurvey No. 586 and 231,Near SKF Bearing, Bavla Bagodara N.H 8A,Kerala, Taluka: Bavla,Ahmedabad, Gujarat, 382220+91- 83201-31437info@rednexpharma.comVisit Website